Aldeyra Therapeutics (ALDX)
(Delayed Data from NSDQ)
$3.31 USD
-0.09 (-2.65%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $3.30 -0.01 (-0.30%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Aldeyra Therapeutics, Inc. [ALDX]
Reports for Purchase
Showing records 21 - 40 ( 43 total )
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Focusing on Reproxalap TRANQUILITY-2 Results Expected 2Q22; With RASP Inhibitor Platform Upside
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
RASP Modulation and How TRANQUILITY-2 Can Reassert Reproxalap; Assuming Coverage With a Buy Rating and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
TRANQUILITY Results Not Tranquil; Remain Hopeful in TRANQUILITY-2 Data in Mid-2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Phase 2 Trial in Dry Eye Disease Shows Positive Results on Ocular Redness
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Ph3 TRANQUILITY Trial Data Coming Soon; Potential NDA Filing in Dry Eye Disease Expected in Early 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Reproxalap TRANQUILITY Trials Remain On Track; ADX-2191 Bringing New Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
A Solid First Quarter and More Catalysts Expected to Come Later This Year; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Positive Phase 3 INVIGORATE Results Bode Well for Reproxalap in Ocular Diseases; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
INVIGORATE AC Top-line Data Upcoming; 4Q20 Recap
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
The Catcher in the Eye; Initiating Coverage With a Buy and $26 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
We are terminating coverage due to the departure from the firm of the covering analyst
Provider: H.C. Wainwright & Co., Inc.
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Q2 Results; Begone Stink Eye if Dry Eye P2 in Sept. Works
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Slight Miss on Component of Primary Seems Like an Itch Aldeyra can Scratch
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Aldeyra Queues Up Another Data-Filled Year With New Dry Eye Candidate
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Q3 Reinforces That 2017 Will Be the Pivotal Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Extinguishing Inflammation With New Programs; Especially Dry Eye
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Trapping Season Opens Early-Biggest Drug Target You''ve Never Heard of; Initiating with $18 Target
Provider: H.C. Wainwright & Co., Inc.
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Maneuvering Through a Clinical Development Hiccup; New $13 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
On Track to Report Clinical Data in 2H15; Reiterate Buy
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: RAMAKANTH S